GlassScriptPhysician profile
Keshav S Bhat
NPI 1336134485
$4,999.23
in general payments reported to CMS, 2019-2025
12 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $1,248 · 2021: $77.21 · 2022: $905 · 2023: $625 · 2024: $156 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553 · Travel and Lodging: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.66 |
| Travel and Lodging | $704.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,939.44 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $1,457.53 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $809.89 | 2019-2025 | Dailies Total1, Precision 1, Total30 |
| Bausch & Lomb Americas INC. | $170.25 | 2022-2025 | Vyzulta, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.72 | 2019-2021 | |
| Abbvie INC. | $124.98 | 2022 | |
| Allergan, INC. | $115.98 | 2022 | |
| Optos, INC. | $102.24 | 2019 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $30.24 | 2025 | Xdemvy |
| Notal Vision, INC. | $22.96 | 2025 | Foresee Home |
| Biotissue Holdings INC. | $19.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keshav Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.